Intra-Cellular Therapies Inc
NASDAQ:ITCI
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
59.07
91.57
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Selling, General & Administrative
Intra-Cellular Therapies Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Selling, General & Administrative
-$471.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
-48%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$22.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
Intra-Cellular Therapies Inc
Glance View
Intra-Cellular Therapies Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for neuropsychiatric and neurological disorders. Founded in 2002 and based in New York City, the company focuses on addressing significant unmet medical needs in mental health, a field that has historically seen limited advancements. Its flagship product, Caplyta (lumateperone), is an atypical antipsychotic that has gained traction for its efficacy in treating schizophrenia and, more recently, bipolar depression. The approval of Caplyta by the U.S. FDA in December 2019 marked a significant milestone, positioning Intra-Cellular Therapies as a key player in the mental health space and enabling it to generate substantial revenue streams while establishing strategic partnerships for further drug development. As Intra-Cellular Therapies continues to expand its portfolio, the company is actively conducting clinical trials for additional indications beyond schizophrenia and bipolar disorder, targeting conditions like major depressive disorder and autism spectrum disorder. With a robust pipeline and an innovative approach to exploring intracellular signaling pathways, the company's research is poised to unlock new treatment modalities within the neuropsychiatric domain. For investors, Intra-Cellular Therapies presents a compelling opportunity, backed by a dedicated team and growing market demand for effective mental health treatments. Their commitment to changing the landscape of neuropsychiatric care, coupled with an emphasis on scientific research and patient outcomes, makes them a company to watch as they seek to transform lives and expand their influence in the biopharmaceutical arena.
See Also
What is Intra-Cellular Therapies Inc's Selling, General & Administrative?
Selling, General & Administrative
-471.5m
USD
Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Selling, General & Administrative amounts to -471.5m USD.
What is Intra-Cellular Therapies Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-48%
Over the last year, the Selling, General & Administrative growth was -18%. The average annual Selling, General & Administrative growth rates for Intra-Cellular Therapies Inc have been -23% over the past three years , -56% over the past five years , and -48% over the past ten years .
You don't have any saved screeners yet
